PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- The 53 most innovative companies in healthcare (Advisory Board)
- Delaying DOAC after colonoscopy: Weighing the risks (MDedge)
- Practice-changing takeaways from the 2026 Gut Microbiota Summit: A clinical reality check (MDLinx)
- ‘Phenomenal’ Tech May Boost Adenoma Detection in Colonoscopy (Medscape)
- CEO of America’s largest public hospital system says he’s ready to replace radiologists with AI (Radiology Business)
- OpenEvidence and Tandem Partner to Streamline Evidence-Based Prescribing and Prior Authorizations (Business Wire)
- Where GI training may fall short (Becker’s GI & Endoscopy)
- AI gut health startups are selling answers that science can’t back up (PitchBook)
